FDA Expands Approval of Johnson & Johnson's Imaavy for Warm Autoimmune Hemolytic Anemia

The U.S. Food and Drug Administration (FDA) has expanded the approval of Johnson & Johnson's drug Imaavy to treat warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older who are currently or were previously treated with steroids. This marks Imaavy as the first treatment cleared for this rare, life-threatening blood disorder, where the immune system destroys red blood cells.